Cannabis-Hyperemesis-Syndrom

 

 Buy Article Permissions and Reprints

Zusammenfassung

Vorgestellt wird der Verlauf einer am ehesten durch Cannabis hervorgerufenen zyklischen Hyperemesis bei einer cannabisabhängigen, aber sonst gesunden jungen Frau. Die zyklische Hyperemesis entwickelte sich im zeitlichen Zusammenhang mit einem vermehrten Cannabiskonsum und remittierte komplett innerhalb weniger Tage in einer beschützten abstinenten Umgebung. Genauso wie die zunehmend in der Literatur berichteten Fälle besserte sich die Hyperemesis durch heißes Duschen oder Baden. Diese Thermosensitivität in Kombination mit den hier erstmals gefundenen laborchemischen Hinweisen auf eine zeitgleiche reversible zentrale Hyperthyreose lassen an eine Beteiligung des hypothalamischen Cannabinoidsystems an der zyklischen Hyperemesis denken. Auch während einer gut 4-monatigen ambulanten Nachsorge trat bei kontrollierter Cannabisabstinenz kein Erbrechen mehr auf.

Abstract

We present the course of cyclical hyperemesis most likely induced by cannabis in a young cannabis-dependent, but otherwise healthy female adult. Cyclical hyperemesis developed in parallel to increasing cannabis inhalation, and remitted completely within a few days of abstinence in a protective inpatient setting. Just as in those increasing cases which can be found in literature, the hyperemesis improved by taking a hot shower or bath at the beginning of the detoxification. This thermosensitivity, along with the detection of a central disturbance of the thyroid axis, points to the hypothalamic cannabinoid system being involved in cannabis-induced cyclical hyperemesis. The patient was followed up for 4 months without any re-occurrence of the syndrome during controlled cannabis abstinence.

Literatur

• 1 Talley N J. Functional nausea and vomiting.  Aust Fam Physician. 2007;  36 694-697
  Google Scholar
• 2 Sullivan S. Cannabinoid hyperemesis.  Can J Gastroenterol. 2010;  24 284-285
  Google Scholar
• 3 Allen J H, Moore G M, Twartz J C. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.  Gut. 2004;  53 1566-1570
  Google Scholar
• 4 Wallace de D, Martin A L, Park B. Cannabinoid hyperemesis: marijuana puts patients in hot water.  Australas Psychiatry. 2007;  15 156-158
  Google Scholar
• 5 Moore G M. Value of the single case report. Marijuana, vomiting and compulsive bathing: a new clinical syndrome?.  Aust N Z J Psychiatry. 2005;  39 1046
  Google Scholar
• 6 Watts de M. Cannabinoid hyperemesis presenting to a New Zealand hospital.  NZ Med J. 2009;  122 116-118
  Google Scholar
• 7 Boeckxstaens G E. Cannabinoid hyperemesis with the unusual symptom of compulsive bathing.  Ned Tijdschr GeneeskdNed. 2005;  149 1468-1471
  Google Scholar
• 8 Alfonso M oreno V, Ojesa F, Moreno-Osset E. Cannabinoid hyperemesis.  Gastroenterol Hepatol. 2006;  29 434-435
  Google Scholar
• 9 Ochoa-Mangado E, Jiménez Giménez M, Salvador Vadillo E et al. Cyclical hyperemesis secondary to cannabis abuse.  Gastroenterol Hepatol. 2009;  32 406-409
  Google Scholar
• 10 Budhraja V, Narang T, Azeez S. Cannabinoid hyperemesis syndrome: cyclic vomiting, chronic cannabis use, and compulsive bathing.  Pract Gastroenterol. 2008;  32 78-80
  Google Scholar
• 11 Chepyala P, Olden K W. Cyclic vomiting and compulsive bathing with chronic cannabis abuse.  Clin Gastroenterol Hepatol. 2008;  6 710-12
  Google Scholar
• 12 Chang Y E, Windish D M. Cannabinoid hyperemesis.  Mayo Clin Proc. 2009;  84 76-78
  Google Scholar
• 13 Donnino M W, Cocchi M N, Miller J et al. Cannabinoid hyperemesis: A case series.  J Emerg Med. 2009;  [Epub ahead of print]
  Google Scholar
• 14 Sontineni P, Chaudhary S, Sontineni V et al. Cannabinoid hyperemesis syndrome: clinical diagnosis of an unrecognised manifestation of chronic cannabis abuse.  World J Gastroent. 2009;  15 1264-1266
  Google Scholar
• 15 Soriano-Co M, Batke M, Cappell M S. The Cannabis Hyperemesis Syndrome Characterized by Persistent Nausea and Vomiting, Abdominal Pain, and Compulsive Bathing Associated with Chronic Marijuana Use: A Report of Eight Cases in the United States.  Dig Dis Sci. 2010;  55 3113-119
  Google Scholar
• 16 Pijlman F TA, Rigter S M, Hoek J et al. Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops.  Addict Biol. 2005;  10 171-180
  Google Scholar
• 17 EMCDDA .Annual report 2010: the state of the drugs problem in Europe: Cannabis. http://www.emcdda.europa.eu/online/annual-report/2010/cannabis/2
  Google Scholar
• 18 Budney A J, Novy P L, Hughes J R. Marijuana withdrawal among adults seeking treatment for marijuana dependence.  Addiction. 1999;  94 1311-1321
  Google Scholar
• 19 Bonnet U, Scherbaum N. Cannabis use disorders. Part I: Pharmacology, Epidemiology and Therapy.  Fortschr Neurol Psychiat. 2010;  78 297-304
  Google Scholar
• 20 Wargo K A, Geveden B, McConnell V J. Cannabinoid-induced pancreatitis: a case series.  JOP. 2007;  8 579-583
  Google Scholar
• 21 Hamilton M. The assessment of anxiety states by rating.  Brit J Med Psychol. 1959;  32 50-55
  Google Scholar
• 22 Hamilton M. A rating scale for depression.  J Neurol Neurochirurg Psychiat. 1960;  23 56-62
  Google Scholar
• 23 Grauwiler S B, Drewe J, Scholer A. Sensitivity and specifity of urinary cannabinoid detection with two immunoassays after controlled oral administration of delta-9-tetrahydrocannabinol to humans.  Ther Drug Monit. 2008;  30 1114-1124
  Google Scholar
• 24 Roca R P, Blackmann M R, Ackerly M B et al. Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism.  Endocr Res. 1990;  16 415-447
  Google Scholar
• 25 Arem R, Cusi K. Thyroid function testing in psychiatric illness. Usefulness limitations.  Trends Endocrinol Metab. 1997;  8 282-287
  Google Scholar
• 26 Bonnet U, Scherbaum N. Cannabis use disorders. Part II: Psychiatric and somatic sequelae and comorbidities.  Fortschr Neurol Psychiat. 2010;  78 360-370
  Google Scholar
• 27 Machado Rocha F C, Stéfano S C, De Cássia Haiek R et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis.  Eur J Cancer Care. 2008;  17 431-443
  Google Scholar
• 28 Cota D, Steiner M A, Marsicano G et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis.  Endocrinology. 2007;  148 1574-81
  Google Scholar
• 29 Benarroch E E. Thermoregulation: recent concepts and remaining questions.  Neurology. 2007;  69 1293-1297
  Google Scholar
• 30 Steiner M A, Wotjak C T. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis.  Prog Brain Res. 2008;  170 397-432
  Google Scholar
• 31 Brown T T, Dobs A S. Endocrine effects of marijuana.  J Clin Pharmacol. 2002;  42 (Suppl 1) 90S-96S
  Google Scholar
• 32 Wenger T, Moldrich G. The role of endocannabinoids in the hypothalamic regulation of visceral function.  Leukot Essent Fatty Acids. 2002;  66 301-330
  Google Scholar
• 33 Glass M, Dragunow M, Faull R LM. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain.  Neuroscience. 1997;  77 299-318
  Google Scholar
• 34 Shelke A R, Mustian K M, Morrow G R. The pathophysiology of treatment-related nausea and vomiting in cancer patients: current models.  Indian J Physiol Pharmacol. 2004;  48 256-268
  Google Scholar
• 35 Baker P D, Morzorati S L, Ellet M L. The pathophysiology of chemotherapy-induced nausea and vomiting.  Gastroenterol Nurs. 2005;  28 469-480
  Google Scholar
• 36 Aviello G, Romano B, Izzo A A. Cannabinoids and gastrointestinal motility: animal and human studies.  Eur Rev Med Pharmacol Sci. 2008;  12 (Suppl 1) 81-93
  Google Scholar
• 37 Maywood E S, O’Neill J, Wong G K et al. Circadian timing in health and disease.  Prog Brain Res. 2006;  153 253-269
  Google Scholar
• 38 Acuna-Goycolea C, Obrietan K, Pol A N. Cannabinoids excite circadian clock neurons.  J Neurosci. 2010;  30 10061-10066
  Google Scholar
• 39 Vaziri N D, Thomas van den R, Sterling M et al. Toxicity with intraveneous injection of crude marijuana extract.  Clin Toxicol. 1981;  18 353-366
  Google Scholar
• 40 Smith P F, Ashton J C, Darlington C L. The endocannabinoid system: a new player in the neurochemical control of vestibular function?.  Audiol Neurotol. 2006;  11 207-212
  Google Scholar
• 41 Morrow G R, Roscoe J A, Hickok J T et al. Nausea and emesis: evidence for a biobehavioral perspective.  Support Care Cancer. 2002;  10 96-105
  Google Scholar

Prof. Dr. med. Udo Bonnet

Klinik für Psychiatrie und Psychotherapie, LVR-Klinikum Essen, Universität Duisburg/Essen

Virchowstr. 174

45147 Essen

Email: udo.bonnet@uni-due.de